ANTI-ARRHYTHMICS AND WARFARIN. Dr Nithish Jayakumar

Similar documents
Mr. Eknath Kole M.S. Pharm (NIPER Mohali)

Antiarrhythmic Drugs

Pediatrics ECG Monitoring. Pediatric Intensive Care Unit Emergency Division

Chapter 9. Learning Objectives. Learning Objectives 9/11/2012. Cardiac Arrhythmias. Define electrical therapy

Rhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014

1 Cardiology Acute Care Day 22 April 2013 Arrhythmia Tutorial Course Material

Cardiac Arrhythmias. For Pharmacists

Dysrhythmias. Dysrythmias & Anti-Dysrhythmics. EKG Parameters. Dysrhythmias. Components of an ECG Wave. Dysrhythmias

Dysrhythmias 11/7/2017. Disclosures. 3 reasons to evaluate and treat dysrhythmias. None. Eliminate symptoms and improve hemodynamics

Rate and Rhythm Control of Atrial Fibrillation

Acute Arrhythmias in the Hospitalized Patient

APPROACH TO TACHYARRYTHMIAS

Antiarrhythmic Drugs 1/31/2018 1

Chapter 14. Agents used in Cardiac Arrhythmias

Atrial fibrillation in the ICU

Cardiac arrhythmias. Janusz Witowski. Department of Pathophysiology Poznan University of Medical Sciences. J. Witowski

The most common. hospitalized patients. hypotension due to. filling time Rate control in ICU patients may be difficult as many drugs cause hypotension

Arrhythmias. A/Prof Drew Richardson. The Canberra Hospital May MB BS (Hons) FACEM Grad CertHE MD

Use of Antiarrhythmic Drugs for AF Who, What and How? Dr. Marc Cheng Queen Elizabeth Hospital

ECGs and Arrhythmias: Family Medicine Board Review 2012

ANTI - ARRHYTHMIC DRUGS

Don t Forget the Basics

ECGs and Arrhythmias: Family Medicine Board Review 2009

AF and arrhythmia management. Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire

Arrhythmias (I) Supraventricular Tachycardias. Disclosures

Arrhythmic Complications of MI. Teferi Mitiku, MD Assistant Clinical Professor of Medicine University of California Irvine

PHARMACOLOGY OF ARRHYTHMIAS

B. 14 Antidysrhythmic drugs. a. Classify antidysrhythmics by their electrophysiological actions. Vaughan-Williams classification

Core Content In Urgent Care Medicine

Management of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39

Supraventricular Tachycardia: From Fetus to Adult. Mohamed Hamdan, MD

WHAT DO YOU SEE WHEN YOU STIMULATE BETA

Heart Failure (HF) Treatment

Anti arrhythmic drugs. Hilal Al Saffar College of medicine Baghdad University

Chapter 26. Media Directory. Dysrhythmias. Diagnosis/Treatment of Dysrhythmias. Frequency in Population Difficult to Predict

Atrial Fibrillation 10/2/2018. Depolarization & ECG. Atrial Fibrillation. Hemodynamic Consequences

ARRHYTHMIAS IN THE ICU

This document does not consider management of individual arrhythmias look elsewhere, e.g. OHCM.

Ablation Update and Case Studies. Lawrence Nair, MD, FACC Director of Electrophysiology Presbyterian Heart Group

ARRHYTHMIA SINUS RHYTHM

ARRHYTHMIAS IN THE ICU: DIAGNOSIS AND PRINCIPLES OF MANAGEMENT

Cost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib

Case #1. 73 y/o man with h/o HTN and CHF admitted with dizziness and SOB Treated for CHF exacerbation with Lasix Now HR 136

PEDIATRIC SVT MANAGEMENT

ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΗΛΕΚΤΡΙΚΗ ΑΝΑΤΑΞΗ. ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ Καρδιολόγος, Ε/Α, Γ.Ν.Κατερίνης. F.E.S.C

Arrhythmias. 1. beat too slowly (sinus bradycardia). Like in heart block

I have nothing to disclose.

2) Heart Arrhythmias 2 - Dr. Abdullah Sharif

Basics of Atrial Fibrillation. By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY

Treatment strategy decision tree

Arrhythmias. Simple-dysfunction cause abnormalities in impulse formation and conduction in the myocardium.

Understanding Atrial Fibrillation Management. Roy Lin, MD

Antiarrhythmic Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

Cardiac Arrhythmias & Drugs used in Advanced Life Support and Cardiac Emergencies

Atrial Fibrillation Management in the ED. J Fisher May 2014"

CSI Skills Lab #5: Arrhythmia Interpretation and Treatment

Dos and Don t in Cardiac Arrhythmia. Case 1 -ECG. Case 1. Management. Emergency Admissions. Reduction of TE risk -CHADS 2 score. Hospital Admissions

Review guidance for patients on long-term amiodarone treatment

Treatment of Arrhythmias in the Emergency Setting

Atrial Fibrillation Cases. Dr Paul Broadhurst Consultant Cardiologist

Medical management of AF: drugs for rate and rhythm control

Nathan Cade, MD Brandon Fainstad, MD Andrew Prouse, MD

! YOU NEED TO MONITOR QT INTERVALS IN THESE PATIENTS.

Chapter 16: Arrhythmias and Conduction Disturbances

Atrial Fibrillation and Common Supraventricular Tachycardias. Sunil Kapur MD

SHOCK THE PATIENT. Disclosures. Goals of the Talk. Tachyarrhythmias- Unstable 11/7/2017

Alaska Nurse Practitioner Annual Conference 2009

Management of Arrhythmias The General Practitioners role

DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)

PATIENT WITH ARRHYTHMIA IN DENTIST S OFFICE. Małgorzata Kurpesa, MD., PhD. Chair&Department of Cardiology

ECG Workshop. Carolyn Shepherd And Anya Horne UWE Principles of Cardiac Care

Arrhythmia 341. Ahmad Hersi Professor of Cardiology KSU

ACTIVITY DISCLAIMER DISCLOSURE. Craig Barstow, MD, FAAFP. Learning Objectives. Associated Session(s) Arrhythmias and Dysrhythmias: PBL

Half Moon Bay Treatment of Atrial Fibrillation. Dr. Roger A. Winkle MD. Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital

Adenosine. poison/drug induced. flushing, chest pain, transient asystole. Precautions: tachycardia. fibrillation, atrial flutter. Indications: or VT

EKG Rhythm Interpretation Exam

Antiarrhythmic Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2017

ARRHYTHMIAS IN THE INTENSIVE CARE UNIT

CVD: Cardiac Arrhythmias. 1. Final Cardiac Arrhythmias_BMP. 1.1 Cardiovascular Disease. Notes:

Invasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic

Antidysrhythmics HST-151 1

ECG Interactive Session

La terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO

Adult Acute Myocardial. Infarction

a lecture series by SWESEMJR

ALS MODULE 7 Pharmacology

Drugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification

Controversies in Atrial Fibrillation and HF

UNDERSTANDING YOUR ECG: A REVIEW

Management of acute Cardiac Arrhythmias

Practical Rate and Rhythm Management of Atrial Fibrillation

Dr. Hussam Al-Humadi. Cardiac Arrhythmia

Current Guideline for AF Treatment. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine

ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION

Antiarrhythmic Pharmacology. The Electronics

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.

Patient Examination. Objectives for Presentation RECOGNITION OF COMMON ARRHYTHMIAS THEIR CAUSES AND TREATMENT OPTIONS 9/8/2016

Atrial Fibrillation. Epidemiology. Goals 11/12/2012. Faithful marker for age and underlying cardiopulmonary disease

The pill-in-the-pocket strategy for paroxysmal atrial fibrillation

Step by step approach to EKG rhythm interpretation:

Transcription:

ANTI-ARRHYTHMICS AND WARFARIN Dr Nithish Jayakumar

Contents 1. Anti-arrhythmics Pacemaker and myocardial potentials Drug classes mechanisms; s/e; contra-indications Management of common arrhythmias 2. Warfarin Coagulation cascade Warfarin in VTE mechanisms; s/e; contra-indications; monitoring Warfarin reversal

Pacemaker & myocardial potentials Pacemaker potentials Originate at rapidly conducting tissue SAN AVN Bundle of His Ventricular fibres SAN ordinarily sets the pace [70-80/min] Sympathetic and parasympathetic input Myocardial potentials Stimulated by pacemaker potentials Atrial and ventricular muscle Sympathetic input only

3 2 4 1

Fast Na closes K channels open Plateau due to Ca inflow prolongs action potential Cardiac cell stimulated fast Na channels open Ca channels close increased K outflow for rapid repolarisation Cell membrane returns to resting potential

Anti-arrhythmics Vaughan-Williams classification According to predominant mechanism of action 4 classes Amiodarone; digoxin; adenosine Rx for tachyarrhythmias [Atropine]

Tachyarrhythmias Enhanced automaticity More active than usual (catecholamines; sepsis; electrolyte imbalance) Triggered activity Re-entry A propagating impulse fails to die out after normal activation of the heart and persists to re-excite the heart after expiration of the refractory period

Class Site Mechanism Example I [Ia; Ib; Ic] Block Na channels Reduces action potential duration Ic: flecainide [Amiodarone] II Block beta-1 receptors Negative inotropy/chronotropy Bisoprolol Metoprolol [Amiodarone] III Block K channels (specifically nodal) Increases refractory period Amiodarone Dronedarone Sotalol IV Block Ca channels Negative inotropy/chronotropy Verapamil Diltiazem [Amiodarone]

Atrial tachycardia Atrial flutter Narrow complex Atrial fibrillation AVRT Supraventricular AVNRT Tachyarrythmias Broad complex SVT with aberrant conduction Ventricular Ventricular tachycardia Ventricular fibrillation

Atrial fibrillation Multiple re-entry mechanisms Class I (Na) Class II (Beta-1) Class III (K) Class IV (Ca)

Rate vs rhythm control Atrial fibrillation Indication in AF Mechanism Contraindications Side-effects Flecainide Paroxysmal AF ( pill in the pocket ) Class Ic Structural heart disease LVF Proarrhythmic AV blocks Dizziness

Rate vs rhythm control Atrial fibrillation Indication in AF Mechanism Contraindications Side-effects Amiodarone Maintain sinus rhythm Class III [all classes] AV block Pneumonitis Bradycardia/AV block Hepatitis Photosensitivity Hypo/hyperthyroidism Prolongs QT

Heart failure and AF Atrial fibrillation Avoid class IV (negatively chronotropic) Rate control with beta-blocker ideal Digoxin is alternative when other rx failed Digoxin Indication in AF Rate control in heart failure Mechanism Side-effects Monitoring Increases vagal tone (less so in exercise) Na/K-ATPase inhibitor positively inotropic GI s/e anorexia; N&V; diarrhoea AV block Dizziness Heart rate Renal function renal clearance Hypokalaemia

Digoxin effect therapeutic doses Reverse-tick ST depression

Digitalis toxicity Clinical features Cardiac any arrhythmia; PVC / brady GI symptoms anorexia; N&V; diarrhoea CNS symptoms Visual changes [yellow-green distortion] Drowsiness Lethargy Headache Biochemical features Hyperkalaemia [renal dysfunction] Serum digoxin level Management Digifab (digoxin-specific antibody fragments)

Re-entry mechanism AVN is focus of re-entry AVNRT Class I (Na) Class II (Beta-1) Class III (K) Class IV (Ca)

AVNRT Vagal maneuvers adenosine BB/CaCB/dig Indication in AVNRT Mechanism Contraindications Side-effects Adenosine Termination - A1 receptors at SAN opens K channels - Ca blocker at AVN AF in WPW Severe asthma Severe coronary artery disease Flushing Chest pain Bronchospasm AV block

AF in WPW Accessory pathway with antegrade conduction Class I (Na) Class III (K) Class II (Beta-1) Class IV (Ca) X X Adenosine X

VT Usually secondary to structural heart disease Class I (Na) Class II (Beta-1) Class III (K) Class IV (Ca)

Electrical cardioversion VT Amiodarone Indicated in haemodynamically unstable/pulseless (as per ALS) and haemodynamically stable VT Lidocaine Class Ib

Atropine Atropine Indication Mechanism Contraindications Side-effects Symptomatic bradyarrhythmias Muscarinic receptor antagonist - Inhibits vagal activation at nodes Glaucoma Ileus BPH Anticholinergic effects: - Dilated pupils - Blurred vision - Dry mouth - Tachycardia - Constipation - Urinary retention

Warfarin INR

Warfarin INR is the standardised measure of prothrombin time PT measures extrinsic and common pathways [VII; X; V; II; fibrinogen]

Warfarin Indication Mechanism Contra-indications Cautions Side-effects Monitoring Anticoagulation DVT/PE & AF Inhibits the conversion of vitamin K to its active form - Active vitamin K carboxylates 2, 7, 9, 10 [protein C & S] - Without carboxylation, cannot bind Ca and form effective coagulation complex Haemorrhagic stroke Significant bleeding Pregnancy Liver failure - Increased risk of bleeding [recent surgery; recent ischaemic stroke; recent GI bleed; peptic ulcer; severe hypertension] - Drug interactions [enzyme inducers & inhibitors] - Other interactions [cranberry juice; ETOH] Bleeding Skin necrosis Hepatic dysfunction GI s/e N&V; diarrhoea INR

Warfarin in AF

Warfarin and bleeding risk

Warfarin in DVT/PE Initiated with heparins Heparins continued for minimum 5 days post DVT/PE Once-daily regimen Load with 10/5/5 usually (lower in elderly; liver/renal/heart failure) 10mg od 5mg od 5mg od Check INR each day After initiation protein C and VII levels fall first may be initially procoagulant (warfarin skin necrosis protein C deficiency) Heparins stopped when INR in therapeutic range for 2 consecutive days

INR targets AF 2.5 DVT/PE 2.5 Recurrent DVT/PE 3.5 Metallic valve 3.0-3.5 Warfarin Duration of warfarin therapy First DVT/PE, reversible cause = 3 months Idiopathic first DVT/PE = 3 months or long-term Recurrent DVT/PE = indefinite DVT/PE and cancer = LMWH for 3-6 months then long-term Anticoagulation clinic referral for regular follow-up Yellow book for INR monitoring

Warfarin reversal Major bleeding associated with warfarin: Intracranial haemorrhage GI bleed Urgent surgery 1. Stop warfarin 2. Vitamin K IV 5mg over 20-60mins (12 hrly) 3. Prothrombin complex concentrate [2, 7, 9, 10, protein C & S] Alternative is fresh frozen plasma PCC corrects the defective coagulopathy without risks of transfusion reactions

Warfarin reversal INR >8; minor bleeding 1. Stop warfarin 2. Vitamin K IV 1-3mg 3. Restart warfarin when INR <5.0 INR >8; no bleeding 1. Stop warfarin 2. Vitamin K 1-5mg oral 3. Restart warfarin when INR <5.0 INR 5 8; minor bleeding 1. Stop warfarin 2. Vitamin K IV 1-3mg 3. Restart warfarin when INR <5.0 INR 5 8; no bleeding 1. Hold 1 or 2 doses of warfarin 2. Recheck INR and reduce subsequent maintenance dose

Warfarin reversal Peri-operative 1. Stop warfarin 5 days in advance 2. If high risk bridge with LMWH

Thanks for listening! Good luck! Any questions?